Tofacitinib citrate (Xeljanz)

Pharmacy Author:
Medical and Pharmacy Editor:

GENERIC NAME: Tofacitinib citrate


DRUG CLASS AND MECHANISM: Tofacitinib is an oral drug used for treating rheumatoid arthritis. It belongs to a class of drugs called Janus kinase (JAK) inhibitors. JAKs are enzymes (proteins) that regulate chemical signaling pathways that control biologic processes such as blood formation and the immune response that causes the pain, tenderness and swelling of inflammation. JAKs are found in many cells, especially stem cells in bones and joints. Inhibition of JAKs by tofacitinib prevents inflammation and tissue destruction that is associated with the inflammation of rheumatoid arthritis. Tofacitinib was approved in November 2012.

PRESCRIBED FOR: Tofacitinib is used for moderate-to-severely active rheumatoid arthritis in adults who have had an insufficient response or cannot tolerate methotrexate (Rheumatrex, Trexall).

Tofacitinib may be used by itself or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

SIDE EFFECTS: Side effects of tofacitinib are:

Tofacitinib carries a boxed warning of risk of developing infections that may lead to hospitalization or death.

Patients must be carefully monitored for the development of signs and symptoms of infection before and during the treatment of tofacitinib.

Medically Reviewed by a Doctor on 10/13/2015

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index